Purpose: Chimeric antigen receptor (CAR) T-cell therapy is a potent immunotherapy for
hematologic malignancies, but patients can develop long-term adverse events, including …

ABSTRACT CAR-T cell therapy has established itself as a highly effective treatment for
hematological malignancies. There are currently six commercial CAR-T products that have …

Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports
following chimeric antigen receptor T-cell therapies in the Food and Drug Administration …

Although multiple myeloma is an incurable disease, the past decade has witnessed
significant improvement in patient outcomes. This was brought about by the development of …

T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR
T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the …

Background T-cell–redirecting therapies, such as bispecific antibodies and chimeric antigen
receptor T-cells, exploit the cytotoxic capabilities of the immune system to destroy cells …

Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses
in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with …

Toxicity of CAR T-Cell Therapy for Multiple Myeloma Page 1 Acta Haematol , DOI: 10.1159/000539134
Received: February 14, 2024 Accepted: April 22, 2024 Published online: May 8, 2024 …

Chimeric antigen receptor T-cell (CAR-T) therapy has ushered in a new era for the treatment
of multiple myeloma (MM). Numerous clinical studies, especially those involving B-cell …

Introduction Modern anti-myeloma therapies have broken new ground in the treatment of the
disease, and the incorporation of ide-cel in the treatment landscape represents one of the …